NCT05318807

Personalised Diet, Exercise and Emotional Support for Lung Cancer Patients Having Chemotherapy, Radiotherapy or Immunotherapy Treatment

Status unknown NA Last updated 1 May 2023

What this trial tests

NA trial testing Assessment of level of readiness and need for personalised prehabilitation in Lung Cancer in 30 participants. Status unknown.

Timeline

28 October 2022

Primary endpoint
30 June 2023

1 September 2023

Quick facts

Lead sponsor	Imperial College Healthcare NHS Trust
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	30
Start date	28 October 2022
Primary completion	30 June 2023
Estimated completion	1 September 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

• Assessment of level of readiness and need for personalised prehabilitation
• Formation of a personalised prehabilitation plan
• Daily diary

Conditions studied

• Lung Cancer — all drugs for Lung Cancer →

Sponsor

Imperial College Healthcare NHS Trust

Who can join

Adults 18 to 99, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background

The term 'prehabilitation' refers to a period of time before treatment and often includes diet, exercise and/or wellbeing plans to help patients through their cancer treatment. Prehabilitation has shown to benefit patients having surgery, but there is little research into its use in the oncological setting.

The United Kingdom sees more deaths from lung cancer than any other cancer. 70-80% of lung cancer patients receive oncological treatment. Treatment side effects can have a significant impact on quality of life. Personalised prehabilitation can take into account the challenges patients face, helping patients through treatment.

Aim

To see if a personalised plan of diet, exercise and emotional support can be used in practice for patients having chemotherapy, radiotherapy and/or immunotherapy treatment for lung cancer.

Methods

The study will involve lung cancer patients from Imperial College Healthcare NHS Trust who are:

* Over the age of 18 years old
* Have not had previous lung cancer surgery and
* Are about to start chemotherapy, radiotherapy or immunotherapy treatment

The prehabilitation interventions will be based upon patient need and readiness, assessed using:

* A series of questionnaires
* An assessment of walking
* A measure of grip strength

These will be done prior to, at week three and at week six of a patient's oncological treatment regime. Personalised goals will be agreed at each stage.

Throughout treatment, patients will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood. The diary will also be used to monitor goal adherence.

Public involvement

Patients will be part of a study advisory group, helping with research design and dissemination e.g. with the presentation of findings to the lung cancer support group.

Dissemination

All patients will receive a written summary of findings. Results will be shared in a scientific journal and presented at relevant conferences. Patients will not be identifiable.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Immunosenescence, Physical Exercise, and their Implications in Tumor Immunity and Immunotherapy.
   Yu X, Pei W, Li B, Sun S, et al · · 2025 · cited 13× · PMID 39897036 · DOI 10.7150/ijbs.100948
2. Targeting the Gut Microbiome to Improve Immunotherapy Outcomes: A Review.
   David A, Lev-Ari S. · · 2024 · cited 4× · PMID 39223798 · DOI 10.1177/15347354241269870
3. Is personalised prehabilitation feasible to implement for patients undergoing oncological treatment for lung cancer at a London teaching hospital? Protocol of a feasibility trial.
   Wade-Mcbane K, King A, Urch C, Johansson L, et al · · 2023 · cited 2× · PMID 37460263 · DOI 10.1136/bmjopen-2023-072367